Cover Image
市場調查報告書

Sanofi- 產品平台檢討

Sanofi - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256067
出版日期 內容資訊 英文 203 Pages
訂單完成後即時交付
價格
Back to Top
Sanofi- 產品平台檢討 Sanofi - Product Pipeline Review - 2016
出版日期: 2016年04月13日 內容資訊: 英文 203 Pages
簡介

Sanofi是總公司設立於法國的醫療保健企業。提供癌症,心血管系統疾病,血栓症,糖尿病,中樞神經系統疾病等廣泛領域之處方藥,消費者保健產品,學名藥等產品。

本報告提供Sanofi的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Sanofi的基本資料

  • Sanofi概要
  • 主要資訊
  • 企業資料

Sanofi:R&D概要

  • 主要的治療範圍

Sanofi:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

Sanofi:開發中產品概況

  • 後期階段產品開發中產品
  • 臨床階段的開發中產品
  • 初期階段的開發中產品

Sanofi:藥物簡介

  • (fluticasone propionate + formoterol fumarate)
  • Toujeo
  • mipomersen sodium
  • semuloparin
  • (fexofenadine hydrochloride + phenylephrine hydrochloride)
  • (insulin glargine + lixisenatide)
  • cabazitaxel
  • encephalitis vaccine
  • insulin lispro
  • lixisenatide
  • tetanus + diphtheria + pertussis (acellular) vaccine
  • fexinidazole
  • alemtuzumab
  • coltuximab ravtansine
  • ferroquine
  • isatuximab
  • plerixafor
  • SAR-125844
  • SAR-156597
  • vatelizumab
  • VerorabVax
  • GZ-389988A
  • pilaralisib
  • SAR-408701
  • SAR-421869
  • SAR-422459
  • voxtalisib
  • AVE-8112
  • SAR-113244
  • SAR-228810
  • SAR-252067
  • SAR-405838
  • SAR-405838 + pimasertib hydrochloride
  • SAR-425899
  • SAR-566658
  • ACP-002
  • ACP-003
  • ACP-004
  • AVE-3085
  • BSI-401
  • cyclohexylgriselimycin
  • Drugs for Type 1 Diabetes
  • food allergy vaccine
  • LCB-17
  • MI-51964
  • Monoclonal Antibody Conjugated 5 for Oncology
  • RDX-002
  • Recombinant Proteins for Undisclosed Indication
  • SAR-088
  • SAR-110068
  • SAR-131675
  • SAR-156497
  • SAR-184841
  • SAR-216471
  • SAR-224
  • SAR-244181
  • SAR-296968
  • SAR-396049
  • Small Molecules 1 for Tuberculosis
  • Small Molecules for Malaria
  • Small Molecules to Inhibit DGAT-1 for Metabolic Disorders
  • Small Molecules to Inhibit PI3K Beta for Oncology
  • Vasculotide
  • Labyrinthopeptine A1
  • Monoclonal Antibodies for Infectious Disease
  • SAR-405
  • Small Molecule for Calcific Aortic Valve Stenosis
  • Small Molecule for Dilated Cardiomyopathy
  • Small Molecule for Duchenne Muscular Dystrophy
  • Small Molecules 2 for Tuberculosis
  • Small Molecules 3 for Tuberculosis
  • Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Diabetes
  • Small Molecules to Inhibit Protein Kinase for Multiple Undisclosed Indications
  • Small Molecules to Inhibit Protein Kinase for Undisclosed Indication

Sanofi:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Sanofi:最近的開發平台資訊

Sanofi:開發暫停中的計劃

Sanofi:開發中止的開發中產品簡介

Sanofi:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

Sanofi:主要的製造設施

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08023CDB

Summary

Global Markets Direct's, 'MedImmune, LLC - Product Pipeline Review - 2016', provides an overview of the MedImmune, LLC's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by MedImmune, LLC, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of MedImmune, LLC
  • The report provides overview of MedImmune, LLC including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses MedImmune, LLC's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features MedImmune, LLC's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate MedImmune, LLC's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for MedImmune, LLC
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding MedImmune, LLC's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sanofi Snapshot
    • Sanofi Overview
    • Key Information
    • Key Facts
  • Sanofi - Research and Development Overview
    • Key Therapeutic Areas
  • Sanofi - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Sanofi - Pipeline Products Glance
  • Sanofi - Late Stage Pipeline Products
  • Sanofi - Clinical Stage Pipeline Products
  • Sanofi - Early Stage Pipeline Products
  • Sanofi - Drug Profiles
    • (insulin glargine + lixisenatide)
    • lixisenatide
    • mipomersen sodium
    • semuloparin sodium
    • (fexofenadine hydrochloride + phenylephrine hydrochloride)
    • avanafil
    • cabazitaxel
    • insulin lispro
    • ziv-aflibercept (recombinant)
    • fexinidazole
    • (capecitabine + cyclophosphamide)
    • alemtuzumab
    • artefenomel + ferroquine
    • ataciguat
    • efpeglenatide
    • isatuximab
    • plerixafor
    • SAR-156597
    • sotagliflozin
    • pilaralisib
    • SAR-408701
    • SAR-421869
    • SAR-422459
    • voxtalisib
    • Monoclonal Antibodies to Inhibit Abeta for Alzheimer's Disease
    • SAR-113244
    • SAR-228810
    • SAR-366234
    • SAR-407899
    • SAR-425899
    • SAR-428926
    • SAR-438335
    • SAR-438544
    • SAR-440067
    • SAR-566658
    • ACP-003
    • DCM-1
    • efpeglenatide + HM-12470
    • food allergy vaccine
    • Peptides for Tuberculosis
    • Recombinant Proteins for Pseudomonas aeruginosa Infection
    • SAR-088
    • SAR-110068
    • SAR-131675
    • SAR-156497
    • SAR-184841
    • SAR-216471
    • SAR-224
    • SAR-244181
    • SAR-296968
    • SAR-396049
    • SAR-7334
    • Small Molecule 4 for Tuberculosis
    • Small Molecule to Inhibit Beta Sliding Clamp for Tuberculosis
    • Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds
    • Monoclonal Antibodies for Infectious Disease
    • Monoclonal Antibodies for Neurodegenerative Diseases
    • Peptide for HIV and HSV Infections
    • SAR-405
    • Small Molecule 2 for Tuberculosis
    • Small Molecule 3 for Tuberculosis
    • Small Molecule for Calcific Aortic Valve Stenosis
    • Small Molecule for Duchenne Muscular Dystrophy
    • Small Molecules for Malaria
    • Small Molecules to Inhibit Protein Kinase for Undisclosed Indication
    • Vaccine for Celiac Disease
    • Vaccine for Food Allegy 2
    • Zika virus vaccine
  • Sanofi - Pipeline Analysis
    • Sanofi - Pipeline Products by Target
    • Sanofi - Pipeline Products by Route of Administration
    • Sanofi - Pipeline Products by Molecule Type
    • Sanofi - Pipeline Products by Mechanism of Action
  • Sanofi - Recent Pipeline Updates
  • Sanofi - Dormant Projects
  • Sanofi - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Sanofi - Company Statement
  • Sanofi - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Sanofi - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sanofi, Key Information
  • Sanofi, Key Facts
  • Sanofi - Pipeline by Indication, 2016
  • Sanofi - Pipeline by Stage of Development, 2016
  • Sanofi - Monotherapy Products in Pipeline, 2016
  • Sanofi - Combination Treatment Modalities in Pipeline, 2016
  • Sanofi - Partnered Products in Pipeline, 2016
  • Sanofi - Partnered Products/ Combination Treatment Modalities, 2016
  • Sanofi - Out-Licensed Products in Pipeline, 2016
  • Sanofi - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Sanofi - Pre-Registration, 2016
  • Sanofi - Filing rejected/Withdrawn, 2016
  • Sanofi - Phase III, 2016
  • Sanofi - Phase II, 2016
  • Sanofi - Phase I, 2016
  • Sanofi - Preclinical, 2016
  • Sanofi - Discovery, 2016
  • Sanofi - Pipeline by Target, 2016
  • Sanofi - Pipeline by Route of Administration, 2016
  • Sanofi - Pipeline by Molecule Type, 2016
  • Sanofi - Pipeline Products by Mechanism of Action, 2016
  • Sanofi - Recent Pipeline Updates, 2016
  • Sanofi - Dormant Developmental Projects,2016
  • Sanofi - Discontinued Pipeline Products, 2016
  • Sanofi, Subsidiaries
  • Sanofi, Key Manufacturing Facilities

List of Figures

  • Sanofi - Pipeline by Top 10 Indication, 2016
  • Sanofi - Pipeline by Stage of Development, 2016
  • Sanofi - Monotherapy Products in Pipeline, 2016
  • Sanofi - Combination Treatment Modalities in Pipeline, 2016
  • Sanofi - Partnered Products in Pipeline, 2016
  • Sanofi - Out-Licensed Products in Pipeline, 2016
  • Sanofi - Pipeline by Top 10 Target, 2016
  • Sanofi - Pipeline by Route of Administration, 2016
  • Sanofi - Pipeline by Top 10 Molecule Type, 2016
  • Sanofi - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top